Advertisement
Advertisement
BRTX
BioRestorative Therapies, Inc. Common Stock (NV)
0.21
USDSponsored
-0.02
-8.53%
May 08, 16:00 UTC -4
Closed
After-Market
0.21
0.00
+2.04%
BRTX Earnings Reports
Positive Surprise Ratio
BRTX beat 13 of 16 last estimates.
81%
Next Report
Date of Next Report
May 20, 2026
Estimate for Q1 26 (Revenue/ EPS)
$318.75K
/-$0.20
Implied change from Q4 25 (Revenue/ EPS)
+1493.75%
/-35.48%
Implied change from Q1 25 (Revenue/ EPS)
+1175.00%
/-68.75%
BioRestorative Therapies, Inc. Common Stock (NV) earnings per share and revenue
On Mar 26, 2026, BRTX reported earnings of -0.31 USD per share (EPS) for Q4 25, beating the estimate of -0.37 USD, resulting in a 17.86% surprise. Revenue reached 20.00 thousand, compared to an expected 153.00 thousand, with a -86.93% difference. The market reacted with a +0.41% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 3 analysts forecast an EPS of -0.20 USD, with revenue projected to reach 318.75 thousand USD, implying an decrease of -35.48% EPS, and increase of 1493.75% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Werewolf Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.29
Actual
-$0.28
Surprise
+3.68%
argenx SE - ADR
Report Date
May 07, 2026 For Q1 26
Estimate
$5.47
Actual
$5.52
Surprise
+0.86%
Arrowhead Research Corporation
Report Date
May 07, 2026 For Q2 26
Estimate
-$1.16
Actual
-$0.93
Surprise
+20.32%
ImmunityBio, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-26.05%
Stoke Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.84
Actual
-$0.79
Surprise
+6.34%
ANI Pharmaceuticals, Inc.
Report Date
May 08, 2026 For Q1 26
Estimate
$1.33
Actual
$2.04
Surprise
+54.04%
Harmony Biosciences Holdings, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$0.72
Actual
$0.55
Surprise
-24.16%
CytomX Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.10
Surprise
+18.83%
Tectonic Therapeutic, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.20
Actual
-$1.34
Surprise
-11.07%
ALX Oncology Holdings Inc. Common Stock
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.22
Actual
-$0.17
Surprise
+24.24%
FAQ
What were BioRestorative Therapies, Inc. Common Stock (NV)'s earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, BioRestorative Therapies, Inc. Common Stock (NV) reported EPS of -$0.31, beating estimates by 17.86%, and revenue of $20.00K, -86.93% below expectations.
How did the market react to BioRestorative Therapies, Inc. Common Stock (NV)'s Q4 2025 earnings?
The stock price moved up 0.41%, changed from $0.30 before the earnings release to $0.30 the day after.
When is BioRestorative Therapies, Inc. Common Stock (NV) expected to report next?
The next earning report is scheduled for May 20, 2026.
What are the forecasts for BioRestorative Therapies, Inc. Common Stock (NV)'s next earnings report?
Based on 3
analysts, BioRestorative Therapies, Inc. Common Stock (NV) is expected to report EPS of -$0.20 and revenue of $318.75K for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement